All In Biotech

Drug Trial Radar · NCT02723773

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Efficacy, Safety and Immunogenicity of GSK Biologicals' HZ/su Vaccine GSK1437173A in a Phase IIIb, Open-label, Long-term Follow-up Study (ZOE-LTFU) of Studies 110390/113077 (ZOSTER-006/022) and Assessment of Additional Doses in Older Adults

Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,539

Actual

Start

Apr 16, 2016

Primary completion

Jun 28, 2023

Study completion Jan 30, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 30, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Factorial
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study was a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and included an assessment of 1 or 2 additional doses in two subgroups of older adults.

Conditions

  • Herpes Zoster
  • Herpes Zoster Vaccine

Interventions

  • Herpes Zoster Vaccine GSK1437173ABiological

    Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, OverallTime frame: During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)

Locations

161 sites in 18 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Spring Valley, California

  • GSK Investigational Site

    Hallandale, Florida

  • GSK Investigational Site

    Boise, Idaho

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Columbia, Maryland

  • GSK Investigational Site

    Elkridge, Maryland

  • GSK Investigational Site

    Cary, North Carolina

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Hickory, North Carolina

  • GSK Investigational Site

    Salisbury, North Carolina

  • GSK Investigational Site

    Wilmington, North Carolina

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Wadsworth, Ohio

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Uniontown, Pennsylvania

  • GSK Investigational Site

    Mt. Pleasant, South Carolina

  • GSK Investigational Site

    Bristol, Tennessee

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Newport News, Virginia

  • GSK Investigational Site

    Westmead, New South Wales, Australia

  • GSK Investigational Site

    Wollongong, New South Wales, Australia

  • GSK Investigational Site

    Geelong, Victoria, Australia

  • GSK Investigational Site

    Belo Horizonte, Brazil

  • GSK Investigational Site

    Curitiba, Brazil

  • GSK Investigational Site

    CuritibaPR, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Vancouver, British Columbia, Canada

  • GSK Investigational Site

    Victoria, British Columbia, Canada

  • GSK Investigational Site

    Halifax, Nova Scotia, Canada

  • GSK Investigational Site

    Truro, Nova Scotia, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Woodstock, Ontario, Canada

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.